Therefore, we evaluated the association between tumor PD-L2 and immune signatures such as infiltration of CD45+ cells (CD45 is a general lymphocyte marker), CD8+ cells (CD8 is a cytotoxic T lymphocyte marker), CD45RO+ cells (CD45RO is a memory T lymphocyte marker), PD1+ cells (PD1 is an immunosuppressive lymphocyte marker) and PD-L1 by immunohistochemical analysis of intraepithelial tumor-infiltrating lymphocytes within tumor beds (Fig. 3A). The gene discussed is PTPRC; the disease is neoplasm.